Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$182.7 million.

  • BridgeBio Pharma's Net Income towards Common Stockholders fell 1277.65% to -$182.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$797.1 million, marking a year-over-year decrease of 8163.38%. This contributed to the annual value of -$535.8 million for FY2024, which is 1670.39% up from last year.
  • Per BridgeBio Pharma's latest filing, its Net Income towards Common Stockholders stood at -$182.7 million for Q3 2025, which was down 1277.65% from -$181.9 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Net Income towards Common Stockholders high stood at -$9.9 million for Q2 2022, and its period low was -$265.0 million during Q4 2024.
  • Over the past 5 years, BridgeBio Pharma's median Net Income towards Common Stockholders value was -$157.9 million (recorded in 2023), while the average stood at -$145.0 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 8977.04% in 2022, then crashed by 150205.97% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Net Income towards Common Stockholders (Quarter) stood at -$147.2 million in 2021, then rose by 6.51% to -$137.6 million in 2022, then decreased by 22.21% to -$168.1 million in 2023, then tumbled by 57.63% to -$265.0 million in 2024, then skyrocketed by 31.05% to -$182.7 million in 2025.
  • Its Net Income towards Common Stockholders was -$182.7 million in Q3 2025, compared to -$181.9 million in Q2 2025 and -$167.4 million in Q1 2025.